A purine derivative having an adenine skeleton substituted at N-9 with a erythro-2-hydroxynonan-3-yl group; relative configuration.
ChEBI ID: 63057
| Member | Definition | Role |
|---|---|---|
| 9-(2-hydroxy-3-nonyl)adenine | EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase. | (2R,3S)-EHNA |
| 9-(2-hydroxy-3-nonyl)adenine | EHNA of absolute configuration 2S,3R. | (2S,3R)-EHNA |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (9.76) | 18.7374 |
| 1990's | 8 (19.51) | 18.2507 |
| 2000's | 11 (26.83) | 29.6817 |
| 2010's | 11 (26.83) | 24.3611 |
| 2020's | 7 (17.07) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (4.55%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 42 (95.45%) | 84.16% |